Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...

Jay Lalezari, CEO, CytoDyn, emphasizes how regulatory T cells play a crucial role in tumor progression by enabling cancers to ...

Artificial intelligence is a wildcard in the selection process, most profoundly in its agentic form. AI agents 2 will help ...

Novo Nordisk’s board overhaul signals a decisive return to Foundation-led scientific and operational governance, raising strategic questions about whether the company can sustain U.S. growth and ...